Bone Marrow Microenvironment Could Offer Future Target in CML

News
Article

Modulation of the bone marrow microenvironment with parathyroid hormone may be a feasible way to dramatically reduce counts of leukemia stem cells in chronic myeloid leukemia patients, according to new research in mice.

A small, hypolobated megakaryocyte in a bone marrow aspirate, typical of CML; source: Difu Wu, Wikimedia Commons

Modulation of the bone marrow microenvironment with parathyroid hormone (PTH) may be a feasible way to dramatically reduce counts of leukemia stem cells in chronic myeloid leukemia (CML) patients, according to new research in mice. Reducing leukemia stem cells (LSCs) is a required step on the path to a true cure for the disease.

“Like their normal hematopoietic stem cell counterparts, leukemia stem cells in CML and acute myeloid leukemia (AML) are presumed to reside in specific niches in the bone marrow microenvironment and may be the cause of relapse following chemotherapy,” wrote investigators led by Daniela S. Krause, MD, PhD, of Massachusetts General Hospital in Boston. The study was published in Nature Medicine.

Krause and her colleagues tested transgenic mice bred to have osteoblastic cell-specific expression of an active receptor for PTH and compared them with wild-type mice as recipients of retroviral transduction-transplantation of myeloproliferative neoplasia, a condition that resembles CML. In the mice where the PTH receptor was modified, the cumulative mortality due to that CML-like myeloproliferative neoplasia was significantly decreased (P < .001) and the overall survival of the mice was prolonged (P = .002). Treatment with PTH also yielded a 15-fold reduction in frequency of LSCs in the bone marrow (P = .0006).

In contrast, mice treated in the same way showed an enhancement of oncogene-induced AML. The difference in response suggests that the specific niches where LSCs reside in CML and AML are distinct. The mechanism by which PTH offers a benefit in CML appears to be via release from the microenvironment of transforming growth factor-ß1 (TGF-ß1); the protein exhibits a suppressive effect on CML stem cells.

The investigators also injected total bone marrow cells from seven human untreated chronic phase CML patients into mice pretreated with either saline or PTH. PTH treatment was significantly associated with a decrease in leukemic engraftment (P = .049), a finding that the authors wrote provides support for testing PTH in human subjects with CML.

“Our results suggest that targeting the hematopoietic microenvironment through [parathyroid hormone] may render it hostile for CML cells, raising the possibility of altering the tumor microenvironment as potentially complementary approach to tumor cell-specific therapeutics,” they concluded.

Recent Videos
Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Related Content